Lipid Abnormalities in Persons Living With HIV Infection. by Waters, David D & Hsue, Priscilla Y
UCSF
UC San Francisco Previously Published Works
Title
Lipid Abnormalities in Persons Living With HIV Infection.
Permalink
https://escholarship.org/uc/item/44z0p7dx
Journal
The Canadian journal of cardiology, 35(3)
ISSN
0828-282X
Authors
Waters, David D
Hsue, Priscilla Y
Publication Date
2019-03-01
DOI
10.1016/j.cjca.2018.11.005
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
rdiology 35 (2019) 249e259Canadian Journal of CaReview
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Lipid abnormalities are prevalent among persons living with HIV
infection and contribute to increasing the risk of cardiovascular events.
Antiretroviral therapy (ART) is associated with lipid abnormalities, most
commonly hypertriglyceridemia, but also increases in low-density
lipoprotein cholesterol and total cholesterol. Different classes of ART,
and different drugs within classes, have differing effects on lipid levels,
but in general newer drugs have more favourable effects compared
with older ones. Low-level inﬂammation and chronic immune activa-
tion act on lipids through a variety of mechanisms to make them more
atherogenic. As a consequence, risk is higher than would be expected
for any given cholesterol level. Clinical outcome trials of cholesterol-
lowering therapies have not yet been completed in people living with
HIV, so that treatment decisions depend on extrapolation from studies
in uninfected populations. Traditional risk assessment tools underes-
timate cardiovascular risk in individuals with HIV. Statins are the
mainstay of lipid-lowering drug treatment; however, drugedrug in-
teractions with ART must be considered. Simvastatin and lovastatinReceived for publication August 23, 2018. Accepted November 6, 2018.
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Les anomalies lipidiques sont repandues chez les personnes qui vivent
avec le VIH et contribuent à l’augmentation du risque d’evenements
cardiovasculaires. Le traitement antiretroviral (TARV) est associe aux
anomalies lipidiques, plus frequemment à l’hypertriglyceridemie, mais
aussi à l’augmentation du cholesterol à lipoproteines de basse densite
et du cholesterol total. Les differentes classes de TARV et les differents
medicaments parmi ces classes ont des effets distincts sur les taux de
lipides, mais en general les nouveaux medicaments ont des effets plus
favorables que les anciens medicaments. L’inﬂammation de faible
degre et l’activation chronique du système immunitaire agissent sur
les lipides par divers mecanismes pour les rendre plus atherogènes.
Par consequent, le risque est superieur à ce que l’on s’attendrait pour
tout taux de cholesterol donne. Les etudes sur les resultats cliniques
des traitements hypocholesterolemiants chez les personnes atteintes
du VIH n’etant pas encore achevees, les decisions en matière de
traitement dependent donc de l’extrapolation des resultats des etudes
auprès des populations non infectees. Les outils traditionnelsLipid abnormalities are prevalent among persons living with
HIV infection and are important for several reasons. From a
clinical perspective, HIV increases the risk of cardiovascular
(CV) events to the same extent as traditional risk factors such as
diabetes or hypertension.1,2 Lipid abnormalities are a clear
therapeutic target to decrease this risk. Second, antiretroviral
therapy (ART) has reduced mortality and has turned HIV
infection into a chronic disease; however, ART, particularly
older drugs such as the early protease inhibitors (PIs), are
associated with lipid abnormalities and lipodystrophy.3 ART
also complicates treatment of lipids because of drugedrug in-
teractions. Lipids interact with inﬂammatory markers, and in-
ﬂammatory markers induce changes in lipoproteins to make
them more atherogenic.4 Heightened inﬂammation, highly
atherogenic lipoproteins, and residual HIV infection contribute
to a speciﬁc type of atherosclerosis in HIV, characterized by ahigher prevalence of rupture-prone coronary plaques compared
with “ordinary” atherosclerosis.5
The primary goals of this review are: (1) to describe the
lipid abnormalities associated with HIV; (2) to summarize
how lipoproteins might be inﬂuenced by HIV-associated
inﬂammation; (3) to discuss treatment of lipid abnormalities
in individuals with HIV; and (4) to summarize important
features of other CV risk factors in people living with HIV.Lipid Abnormalities
The onset of HIV infection was associated in one study
with a decrease in total cholesterol, low-density lipoprotein
cholesterol (LDL-C), and high-density lipoprotein cholesterol
(HDL-C), by a mean of 0.78, 0.57, and 0.31 mmol/L,
respectively.6 In a study that compared HIV-infected with
uninfected controls matched for age, sex, and body mass in-
dex, the HIV patients had lower HDL-C and LDL-C levels,
and higher triglyceride, C-reactive protein (CRP), and inter-
leukin (IL)-6 levels.7 Initiation of ART is recommended
nowadays at the time of HIV diagnosis,8 so that the lipid
abnormalities of untreated HIV patients are now limited to
individuals in resource-limited countries for whom treatment
is unavailable.ll rights reserved.
are contraindicated in patients taking protease inhibitors, and the dose
of atorvastatin and rosuvastatin should be limited to 40 mg and 10
mg/d with some ART combinations. Switching from older forms of ART
to lipid-friendly newer ones is a useful strategy as long as virologic
suppression is maintained, but adding a statin lowers low-density li-
poprotein cholesterol more effectively. Studies indicate that lipid ab-
normalities are not treated as aggressively in individuals living with HIV
as they are in uninfected people, making this an opportunity to
improve care.
d’evaluation des risques sous-estiment les risques cardiovasculaires
chez les individus infectes par le VIH. Les statines constituent le pilier
du traitement par hypolipidemiants. Toutefois, les interactions
medicamenteuses avec le TARV doivent être considerees. La simvas-
tatine et la lovastatine sont contre-indiquees chez les patients qui
prennent des inhibiteurs de protease, et la dose respective d’atorvas-
tatine et de rosuvastatine devrait être limitee à 40 mg et à 10 mg/j
avec certaines combinaisons de TARV. Le passage des anciens TARV
vers les nouveaux TARV dont les effets sur le proﬁl lipidique sont fa-
vorables est une strategie utile pourvu que la suppression virologique
soit maintenue, mais l’utilisation supplementaire d’une statine abaisse
plus efﬁcacement le cholesterol à lipoproteines de faible densite.
Les etudes montrent que les anomalies des lipides ne sont pas
traitees aussi energiquement chez les individus qui vivent avec le VIH
qu’elles le sont chez les personnes non infectees et offrent une
occasion d’amelioration des soins.
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Volume 35 2019The effect of ART on lipid levels varies a great deal among
the classes of ART drugs, and even among drugs within the
same class. The effects of speciﬁc ART drugs are often difﬁcult
to ascertain because HIV treatment requires multidrug ther-
apy to limit replication of the virus through multiple mech-
anisms, as depicted in Figure 1.9 HIV drugs approved by the
US Food and Drug Administration according to class are
listed in Table 1, and combinations in Table 2. In general,
PIs, non-nucleoside reverse transcriptase inhibitors
(NNRTIs), and nucleoside reverse transcriptase inhibitor an-
alogues (NRTIs) all increase triglyceride levels and might
adversely affect LDL-C levels.
With initiation of older PIs, LDL-C and triglyceride levels
increase, as do glucose and insulin levels.10 The increase in
cholesterol levels with PIs is thought to be caused by increased
cholesterol absorption rather than increased synthesis.11 In-
creases in LDL-C and triglyceride levels are higher with dual than
with single PI therapy. Important differences have been
described among PIs; in a report from the Data Collection on
Adverse Events of Anti-HIVDrugs (D:A:D) study, ritonavir and
ritonavir-containing regimens increased triglyceride and LDL-C
levels more, whereas saquinavir caused less abnormally low
HDL-C levels, and nelﬁnavir was associated with fewer patients
with high total cholesterol:HDL-C ratio.12 Interestingly, even
after adjustment for lipid levels, cumulative exposure to
lopinavir-ritonavir, indinavir, and didanosine were associated
with increased risk of myocardial infarction (MI).13
In another study, the mean increase in LDL-C with
initiation of a PI was 2.0 mmol/L with ritonavir, 0.8 mmol/L
with indinavir, and 1.2 mmol/L with nelﬁnavir.14 Ritonavir,
but not indinavir or nelﬁnavir, was associated with markedly
elevated plasma triglyceride levels.14 Compared with older PIs,
atazanavir and darunavir have more favourable lipid proﬁles.15
In clinical practice ritonavir might sometimes cause extreme
hypertriglyceridemia with levels greater than 10 mmol/L and
the risk of pancreatitis.16 Nowadays lower doses of ritonavir are
usually used, with correspondingly less hypertriglyceridemia;
however, increased triglyceride levels are also seen with com-
binations of ritonavir-saquinavir and ritonavir-lopinavir.16
NNRTIs also increase LDL-C levels, but do not depress
HDL-C levels.12 AmongNNRTIs, efavirenz was associated with
slightly more patients developing hypercholesterolemia andhypertriglyceridemia compared with nevirapine.12 Efavirenz has
been associatedwith greater increases in total and LDL-Cbut not
total:HDL-C ratio compared with atazanavir-ritonavir.17
Compared with rilpivirine (another NNRTI), efavirenz is asso-
ciated with higher total, HDL-C, LDL-C, and triglyceride
levels.18 The NRTI tenofovir alafenamide, a newer formulation
of tenofovir disoproxil fumarate (TDF), is associated with higher
levels of LDL-C andHDL-C, but similar total cholesterol:HDL-
C ratios compared with tenofovir disoproxil fumarate.19
Overall, the prevalence of hyperlipidemia among people
living with HIV across various studies ranges from 28% to
80%, with hypertriglyceridemia being the most common
abnormality.16 This wide range is understandable, because of
intrinsic differences in study populations and the evolution of
HIV drug treatments. Hypertriglyceridemia in HIV patients
has been related to their higher intake of total fat, saturated
fat, trans fat, and cholesterol compared with HIV-negative
controls.20 Saturated fat intake was strongly correlated with
triglyceride levels, suggesting that increased saturated fat
intake could be targeted for dietary modiﬁcation in HIV
patients.
Second-generation PIs such as atazanavir, the integrase
inhibitors, and the C-C chemokine receptor type 5 coreceptor
antagonist maraviroc have favourable effects on lipids,
particularly compared with older forms of ART, as shown in
Table 3.21 Lipid changes with 2 different integrase inhibitors,
dolutegravir and raltegravir, appear to be similar.22 Most of
the studies documenting these effects compared the newer
agents with standard ART, or against placebo on a back-
ground of standard ART. In practice, suppression of HIV
requires combination therapy, usually with 3-4 drugs. The
effects of several of the most commonly used combinations on
total cholesterol, LDL-C, HDL-C, triglycerides, and
total:HDL-C ratio are illustrated in Figure 2.3
Improvements in surrogate markers of atherosclerosis such
as ﬂow-mediated vasodilatation and carotid intima-media
thickness have been reported with newer ART drugs.21
Interestingly, in one study carotid intima-media thickness
progression was less among participants who initiated ataza-
navir treatment.23 This beneﬁt was attributed to atazanavir-
related increases in bilirubin levels. Higher bilirubin levels,
even within the normal range, appear to protect against
Figure 1. Targets for antiretroviral therapy during the lifecycle of the HIV virus. Multiple drugs with different mechanisms of action are used for
effective treatment. See Table 1 for speciﬁc names of antiretroviral therapy drugs. CCR, C-C chemokine receptor; CXCR, chemokine receptor type 4;
Env, envelope protein; Gag, group speciﬁc antigen; GP120, envelope glycoprotein 120; Pol, reverse transcriptase. Reproduced from Smith et al.9
with permission under Creative Commons License (CC BY 3.0). ª 2013 Smith, de Boer, Brul, Budovskaya and van der Spek.
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Lipid Abnormalities in HIVatherosclerosis in Gilbert syndrome,24 and were associated
with a lower risk of incident cardiovascular disease in in-
dividuals with and without HIV in the Veterans Aging Cohort
Study.25 However, incident events in this study did not
appear to be related to atazanavir use, and the mechanism by
which atazanavir yields beneﬁt, or even whether it does, re-
mains controversial.
Most of the studies described in this section were of relatively
short duration and were usually carried out in North American
or European populations. However, ART is now begun most
often in people living in sub-Saharan Africa, where fewer data
are available on the metabolic effects of treatment. In a recent
meta-analysis of 14 trials of 21,023 individuals assessed be-
tween 2003 and 2014 from this region, ART was associated
with an increased risk of hypertriglyceridemia (relative risk,
2.05; 95% conﬁdence interval [CI], 1.51-2.77).26 The associ-
ations between ART and raised blood pressure, glucose, he-
moglobin A1c, and other lipids were inconsistent across studies.
The use of newer drugs with fewer adverse metabolic
consequences might lead to a reduction in CV events among
patients living with HIV. Initiation of ART in the earliest
stages of HIV infection, as is now recommended,8 reduces
inﬂammation, preserves immunologic function, and might be
expected to reduce the potential of HIV infection to induce
atherosclerosis.Interaction Between Inﬂammation and
Lipoproteins in HIV
In individuals without HIV infection, increased levels of
LDL-C promote cholesterol accumulation and inﬂammation
in the arterial wall. LDL-C within the vessel wall becomes
oxidized and triggers proinﬂammatory pathways. Modiﬁed
LDL-C is engulfed by macrophages, which increases toll-like
receptor activity and leads to increased production of cyto-
kines and chemokines.27 Counter-regulatory mechanisms
oppose these changes. Cellular cholesterol accumulation ac-
tivates adenosine triphosphate (ATP)-binding cassette trans-
porters, which promote the efﬂux of cholesterol onto HDL-C
or apolipoprotein A1, so that cholesterol is transported back to
the liver for excretion.
Acute infections, or lipopolysaccharide administration in
animals, interfere with reverse cholesterol transport at multiple
points.27 HDL-C, which usually is an anti-inﬂammatory li-
poprotein that suppresses monocyte adhesion to the endo-
thelium, becomes proinﬂammatory and loses its protective
effect against monocyte adhesion. The antioxidative properties
of HDL-C are also impaired because of a loss of antioxidant
proteins and accumulation of oxidized phospholipids.26
Macrophage myeloperoxidase, which is induced by inﬂam-
matory stimuli in atherosclerotic plaques, also mediates re-
ductions in HDL-C function via oxidation.
Table 1. Antiretroviral therapy
Class Generic name Abbreviation
Brand
name
FDA
approval
PI Atazanavir ATV Reyataz 2003
PI Darunavir DRV Prezista 2006
PI Fosamprenavir FOS-APV, FPV Lexiva 2003
PI* Ritonavir RTV Norvir 1996
PI Saquinavir SQV Invirase 1995
PI Tipranavir TPV Aptivus 2005
NRTI Abacavir ABC Ziagen 1998
NRTI Emtricitabine FTC Emtriva 2003
NRTI Lamivudine 3TC Epivir 1995
NRTI Tenofovir
fumarate disoproxil
TDF Viread 2001
NRTI Zidovudine AZT Retrovir 1987
NNRTI Doravirine DOR Pifeltro 2018
NNRTI Efavirenz EFV Sustiva 1998
NNRTI Etravirine ETR Intelence 2008
NNRTI Nevirapine NVP Viramune 1996
NNRTI Rilpivirine RPV Edurant 2011
CCR5 antag Maraviroc MVC Selzentry 2007
II Dolutegravir DTG Tivicay 2013
II Raltegravir RAL Isentress 2007
FI Enfuvirtide T-20 Fuzeon 2003
PE Cobicistat COBI Tybost 2014
PAI Ibalizumab IBA Trogarzo 2018
antag, antagonist; CCR5, C-C chemokine receptor type 5; FDA, US Food
and Drug Administration; FI, fusion inhibitor; II, integrase inhibitor;
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; PAI, postattachment inhibitor; PE, pharma-
cokinetic enhancer; PI, protease inhibitor.
* Although ritonavir is a PI it is generally used as a pharmacokinetic
enhancer.
Data from the US Department of Health and Human Services.95
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because of their involvement in the pathogenesis of HIV
infection. The gut is the portal of entry for HIV and mac-
rophages. Because of microbial translocation, plasma levels of
lipopolysaccharide and other microbial products, are increased
in HIV-infected people.28 Lipopolysaccharide reduces ATP-
binding cassette transporter activity, HDL-C function, and
reverse cholesterol transport.29 Monocytes exposed to serum
from HIV-infected patients are more likely to transform into
foam cells than monocytes exposed to serum from uninfected
persons.30 Thus, monocyte and HDL-C dysfunction probably
contribute to reduced reverse cholesterol transport in HIV
infection, likely driven by chronic immune activation.4
Circulating markers of monocyte activation (sCD14) predict
mortality in HIV31 and sCD163, a marker of macrophage
activation, is associated with plaque in coronary lesions in
HIV patients.32 Compared with uninfected controls, partici-
pants infected with HIV in one study had heightened
inﬂammation assessed using 18ﬂuorine-2-deoxy-D-glucose
positron emission tomography (FDG-PET), which was asso-
ciated with a circulating marker of monocyte and macrophage
activation.33 Taken collectively, these data suggest that
monocytes play a unique and important role in HIV-related
atherosclerosis.
One aspect of HDL-C function can be assessed by
cholesterol efﬂux capacity, a measurement that has been
shown to predict future CV events in the general popula-
tion.34 Among persons living with HIV, receiving ART, and
with relatively benign lipid proﬁles, cholesterol efﬂux capacitywas shown to be impaired.35 LDL-C particle number was
increased and particle size decreased, and there was a decrease
in large protective HDL-C particles. Thus, persons living with
HIV have an underlying atherogenic lipid proﬁle even when
standard lipid measurements do not appear alarming.
Oxidized LDL-C and HDL-C levels are elevated in HIV-
infected individuals, and might drive monocyte and endothe-
lial cell activation.36 Oxidized lipoproteins are associated with
inﬂammatory biomarkers (IL-6, CRP, and D-dimer) and
multiple markers of immune activation.37 In one study,
oxidized LDL-C levels were independently associated with
carotid intima-media thickness in HIV.38 It remains unclear as
to whether targeting oxidized LDL-C will translate into clinical
beneﬁt because in clinical trials of uninfected individuals,
antioxidant vitamins did not reduce CV events.
To summarize, the low-grade inﬂammation of chronic
HIV infection impairs reverse cholesterol transport, and in-
duces proinﬂammatory changes in lipids, leading to athero-
genesis. In turn, these abnormal lipids stimulate inﬂammatory
pathways and immune activation, factors that independently
contribute to atherosclerosis in HIV. Markers of chronic
inﬂammation and immune activation remain elevated in the
setting of effectively treated HIV infection39 and are strongly
predictive of mortality and CV events.40 Thus, aggressive
treatment of lipids and HIV infection, and likely chronic
inﬂammation as well, appear to be a reasonable approach to
reduce the risk of CV events in this population.Treating Lipids in HIV Patients
Diet and lifestyle optimization should form the foundation
for treatment of lipids in persons living with HIV.41 As with
all overweight individuals, caloric restriction and exercise
should be used to attain ideal body weight. Reducing carbo-
hydrate intake can have a favourable effect on triglyceride
levels. In one report, fasting triglyceride levels and adipose
tissue mass decreased, and muscle mass increased in HIV-
infected men with hypertriglyceridemia after 16 weeks of
resistance training.42 Nevertheless, diet and exercise are by
themselves rarely sufﬁcient treatment.43
A large number of controlled clinical trials have docu-
mented that LDLeC-lowering, usually with statins, reduces
the risk of CV events across a broad spectrum of patients
without HIV infection. Similar data are not available for
people living with HIV; however, the Randomized Trial to
Prevent Vascular Events in HIV (REPRIEVE), launched in
2015, will address this issue.44 In this trial 6500 HIV-infected
participants without known CV disease will be randomized to
pitavastatin 4 mg/d or to placebo with a planned average
follow-up of 4 years. The primary end point of REPRIEVE
will be a composite of CV mortality, MI, stroke or transient
ischemic attack, unstable angina, peripheral artery disease, and
arterial revascularization.
As previously noted, coronary lesions in persons living with
HIV are more likely to be noncalciﬁed, and thus prone to
rupture compared with lesions in uninfected individuals. Even
after adjustment for coronary risk factors, coronary artery
plaque, especially noncalciﬁed plaque, is more prevalent and
extensive in HIV-infected men compared with controls.45 In a
meta-analysis of 9 studies with 1229 persons with HIV and
1029 controls, noncalciﬁed coronary plaques were much more
Table 2. Combination HIV drugs
Combination drugs (abbreviations) Brand name FDA approval
Abacavir, lamivudine (ABC/3TC) Epzicom 2004
Abacavir, dolutegravir, lamivudine
(ABC/DTG/3TC)
Triumeq 2014
Abacavir, lamivudine, zidovudine
(ABC/3TC/ZDV)
Trizivir 2000
Atazanavir, cobicistat (ATV/COBI) Evotaz 2015
Bictegravir, emtricitabine, tenofovir
alafenamide (BIC/FTC/TAF)
Biktarvy 2018
Darunavir, cobicistat (DRV/COBI) Prezcobix 2015
Darunavir, cobicistat, emtricitabine,
tenofovir alafenamide (DRV/COBI/
FTC/TAF)
Symtuza 2018
Dolutegravir, rilpivirine (DTG/RPV) Juluca 2017
Doravirine, lamivudine, tenofovir
disoproxil fumarate (DOR/3TC/
TDF)
Delstrigo 2018
Efavirenz, lamivudine, tenofovir
disoproxil fumarate (EFV/3TC/
TDF)
Symﬁ 2018
Elvitegravir, cobicistat, emtricitabine,
tenofovir alafenamide fumarate
(EVG/COBI/FTC/TAF)
Genvoya 2015
Elvitegravir, cobicistat, emtricitabine,
tenofovir disoproxil fumarate
(EVG/COBI/FTC/TDF)
Stribild 2012
Emtricitabine, rilpivirine, tenofovir
alafenamide (FTC/RPV/TAF)
Odefsey 2016
Emtricitabine, rilpivirine, tenofovir
disoproxil fumarate (FTC/RPF/
TDF)
Complera 2011
Emtricitabine, tenofovir alafenamide
(FTC/TAF)
Descovy 2016
Emtricitabine, tenofovir disoproxil
fumarate (FTC/TDF)
Truvada 2004
Lamivudine, tenofovir disoproxil
fumarate (3TC/TDF)
Cimduo 2018
Lamivudine, zidovudine (3TC/ZDF) Combivir 1997
Lopinavir, ritonavir (LPV/RTV) Kaletra 2000
FDA, US Food and Drug Administration.
Data from the US Department of Health and Human Services.95
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Lipid Abnormalities in HIVcommon in HIV patients: 58% vs 17%, respectively (odds
ratio, 3.26; 95% CI, 1.30-8.18).5
Evidence from a small, randomized, placebo-controlled trial
indicates that these lesions respond favourably to statins.46 Forty
individuals with HIV, evidence of arterial inﬂammation in the
aorta using FDG-PET, and LDL-C levels< 3.37 mmol/L were
randomized to 1 year of treatment with atorvastatin or placebo.
Atorvastatin reduced noncalciﬁed coronary plaque volumeTable 3. Effects of selected new ART drugs on lipid and related parameters
Maraviroc
Type of drug Entry inhibitor Integra
Effect on lipids Improved TC and LDL-C Improv
regim
Metabolic effects Increased BMI, more new-onset
diabetes
Increas
lipoa
Flow-mediated dilatation Improved No cha
The ﬁndings listed in the table are usually from studies comparing these drugs wi
ART.
ART, antiretroviral therapy; BMI, body mass index; cIMT, carotid intima-media
TGs, triglycerides.
Data from Worm et al.13relative to placebo with a median reduction of 19.4% compared
with an increase of 20.4% in the placebo group (P¼ 0.009). No
difference between the groups was shown for aortic FDG-PET
uptake, but this could only be evaluated in 21 of the 40 subjects.
Several lines of argument suggest that individuals living
with HIV should use statins to reduce the risk of CV events.
The risk of CV events in HIV-infected individuals is
approximately double the risk in uninfected individuals,1 an
increase in risk similar to what is seen with diabetes or
hypertension.2 Statins have anti-inﬂammatory and LDLeC-
lowering properties, a combination that might be particularly
effective in breaking the cycle of inﬂammation and athero-
genic lipoproteins described in the previous section. The effect
of atorvastatin on noncalciﬁed plaques in HIV patients in the
just-described trial is impressive, although the sample size of
the trial was small. In a recent review and meta-analysis, statin
treatment was reported to effectively reduce total, LDL-C,
and noneHDL-C, with a small increase in HDL-C and no
signiﬁcant change in triglycerides among individuals with
HIV.47 Despite the LDLeC-lowering effect of statins, their
effect in lowering inﬂammatory marker levels such as CRP
and IL-6 are less pronounced than the response seen in
uninfected persons.48 In the absence of outcomes data from
large clinical trials, it might be worth noting that a meta-
analysis of more than 35,000 individuals living with HIV
showed that statin use was associated with a 33% reduction in
all-cause mortality.49 Finally, it has been suggested on the
basis of observational data that statins, presumably because of
their anti-inﬂammatory effect, might reduce the incidence of
malignancies in people with HIV.50
With the exception of the 2016 European Society of Cardi-
ology/European Atherosclerosis Society guidelines,51 cholesterol
guidelines do not address management of persons living with
HIV. The European Society of Cardiology/European Athero-
sclerosis Society guidelines recommend dietary changes and
exercise, as well as switching, when feasible, to more lipid-
friendly ART. The guidelines also state that statins should be
considered to achieve the target LDL-C level for high-risk pa-
tients, namely 2.8 mmol/L. As in subjects without HIV infec-
tion, underlying causes of dyslipidemia such as hypothyroidism
should be ruled out.
The 2013 American College of Cardiology (ACC)/Amer-
ican Heart Association (AHA) guidelines recommend
consideration of cholesterol-lowering treatment for individuals
40-79 years old with an LDL-C level of 1.8-5.0 mmol/L and a
10-year risk for a CV event of 7.5% or higher. Unfortunately,Raltegravir Atazanavir
se inhibitor Protease inhibitor
ed TC, LDL-C, TGs vs most
ens
Improved TC, LDL-C, TGs
ed BMI, truncal fat, less
trophy
Increased truncal fat vs some regimens
nge No change; decreased cIMT
th other commonly used ART drugs, or with placebo against a background of
thickness; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol;
Figure 2. Effects of common combinations of antiretroviral therapy on lipid levels. HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Reproduced from Lake and Currier3 from The Lancet with permission from Elsevier.
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Volume 35 2019the usual risk assessment tools are inaccurate in the setting of
HIV. For example, in one recent study, high-risk coronary
plaque morphology was seen on computed tomography
angiography in 36% of 108 HIV patients, but the 2013 ACC/
AHA guidelines would recommend statins for only 19% of
them.52 Similarly, in another study the guidelines fail to
recommend statin therapy for two-thirds of individuals with
HIV who had carotid plaque on ultrasound imaging.53
CV risk prediction using either Framingham or the 2013
ACC/AHA risk calculators systematically underestimates risk
in HIV. Risk assessment tools have been designed speciﬁcally
for HIV populations. One of them is on the basis of 1010 CV
events that occurred in 32,663 HIV-positive persons from 20
countries in Europe, and Australia.54 The detailed model in-
cludes age, sex, systolic blood pressure, smoking status, family
history of CV disease, diabetes, total cholesterol, HDL-C, CD4
lymphocyte count, cumulative exposure to PIs and NRTIs, and
current use of abacavir. A reduced model excluded ART and
current use of abacavir. The model performed better than the
Framingham Risk Score even after the Framingham Risk Score
had been recalibrated to the HIV population.
The 2018 AHA/ACC guidelines have recently been pub-
lished.55 They mention HIV as a “risk enhancer” and make 3
recommendations for adults with chronic inﬂammatory disor-
ders or HIV: (1) that these risk enhancers favour opting for
moderate or high-intensity statin therapy in a discussion of risk;
(2) that a risk assessment, including fasting lipid proﬁle, be done
before and 4-12 weeks after starting ART; and (3) for adults
with rheumatoid arthritis, that risk assessment be repeated 2-4
months after the inﬂammatory disease has been controlled.55
Drugedrug interactions must be considered when initi-
ating lipid-lowering drugs in persons living with HIV. Table 4summarizes the hepatic metabolic pathways and ART in-
teractions for each of the 7 statins. A systemic review of 18
clinical trials in HIV-infected patients receiving ART
conﬁrmed that statin administration is safe when drugedrug
interactions are accounted for.56 Simvastatin and lovastatin are
contraindicated with PIs because of the risk of rhabdomyolysis
from high statin blood levels.16 Similarly, no more than 40
mg/d of atorvastatin should be used for individuals taking
ritonavir-boosted PIs. Rosuvastatin blood levels are increased
when used with atazanavir/ritonavir and lopinavir/ritonavir, so
limiting the rosuvastatin dose to 10 mg is advised with these
drugs.57 Pravastatin and ﬂuvastatin are safe but do not lower
LDL-C as much as atorvastatin or rosuvastatin. These weaker
statins were widely used after the introduction of ART, but
are less popular now because of the growing realization, re-
ﬂected in contemporary guidelines, that greater degrees of
LDLeC-lowering produce greater CV event reduction.58
Although not available in Canada, pitavastatin is theoretically
a good choice for individuals living with HIV, because at higher
doses its LDLeC-lowering effect is moderate, and because its
metabolism is via glucuronidation, drugedrug interactions are
avoided.59 In a randomized, double-blind comparison study in
252 subjects with HIV, pitavastatin 4 mg/d reduced LDL-C by
31% and pravastatin 40 mg/d reduced LDL-C by 21%, with
similar low rates of adverse events in the 2 treatment groups.60
Levels of soluble CD14, oxidized LDL-C, and lipoprotein-
associated phospholipase 2 were signiﬁcantly lower in the pit-
avastatin group compared with the pravastatin group.61
As with other patients, statins should be the mainstay of
lipid-lowering drug therapy for persons living with HIV.16,51
Several studies indicate that statins are underused in the
setting of HIV.59,62,63
Table 4. Metabolic pathways of statins and interactions with ART
Drug Metabolism Lipophilic ART interactions Comment
Lovastatin CYP3A4 Yes PI, NNRTI Limited efﬁcacy
Simvastatin CYP3A4 Yes PI, NNRTI Contraindicated
Pravastatin Partial hepatic No PI Limited efﬁcacy
Fluvastatin CYP2C9, CYP3A4 Yes Limited efﬁcacy
Atorvastatin CYP3A4 Yes PI More potent
Rosuvastatin CYP2C9 (< 10%) No PI More potent
Pitavastatin Glucuronidation Yes Least D-D interaction
ART, antiretroviral therapy; D-D, drugedrug; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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ezetimibe is a safe option, albeit with limited LDLeC-
lowering efﬁcacy.64 Ezetimibe could be considered as add-on
therapy for very high-risk individuals with HIV who do not
achieve satisfactory LDL-C lowering with statins. Bile acid
sequestrants are not recommended in HIV-infected in-
dividuals because they increase triglyceride levels and their
effects on the absorption of antiretroviral drugs have not been
studied.50 Add-on therapy can be problematic for individuals
with HIV because they often already suffer from a high pill
burden because of ART and other medications.
We have reported high proprotein convertase subtilisin/kexin
type 9 (PCSK9) levels in the setting of HIV,65 and are currently
investigating PCSK9 inhibitors in a randomized, placebo-
controlled trial as a potential treatment to reduce CV risk us-
ing multimodality assessment of coronary plaque, arterial
inﬂammation, and endothelial function for individuals with
HIV.66 PCSK9 inhibitors have inherent advantages in this
circumstance, including profound LDLeC-lowering, a reduc-
tion in pill burden, avoidance of the drugedrug interactions of
statins, and ease of use in patients with chronic liver disease, a
common problem in this population.
Switching ART to drugs that do not adversely affect lipid
levels is a worthwhile strategy as long as viral suppression is
maintained. Switching from older PIs to integrase inhibitors
has been shown to improve lipid levels, but at the cost of an
increased risk of virologic failure,67 and thus is not recom-
mended for individuals with this history. In another study of
415 subjects with HIV and high CV risk, half were ran-
domized to continue a ritonavir-boosted PI regimen and half
were switched to dolutegravir, an integrase inhibitor.68 After
48 weeks, no difference between the treatment groups was
seen for virologic failure, but total cholesterol, LDL-C, and
triglyceride levels all improved (P < 0.0001) in the dolute-
gravir group. Additional use of a statin might be preferable to
switching for those not already taking a statin; in one study
the additional use of rosuvastatin 10 mg/d yielded better lipid
results and was better tolerated compared with switching.69
Hypertriglyceridemia is a common ﬁnding in individuals
with HIV and might be related to ART or HIV itself.
Reducing alcohol and carbohydrate intake has a favourable
effect in persons with or without HIV infection. Consider-
ation should be given to a change in ART to drugs that induce
less hypertriglyceridemia. Fibrates reduce triglycerides, often
at low doses, but have a drugedrug interaction with statins
and some types of ART; for example, the lopinavir-ritonavir
PI combination greatly reduces gemﬁbrozil absorption.70
Monitoring of hepatic enzymes and creatine phosphokinase
levels is advised for patients taking ART, a statin, and aﬁbrate. Fish oil has been shown to reduce triglyceride levels in
persons with HIV and hypertriglyceridemia, and has the
advantage of no important drugedrug interactions; however,
ﬁsh oil does increase LDL-C levels modestly.71,72 When tri-
glycerides exceed 10 mmol/L, pancreatitis is a serious risk;
lower levels of hypertriglyceridemia probably increase CV risk.
If pancreatitis does develop, the offending drug must be
withdrawn and supportive care instituted.73
The recently published Reduction of Cardiovascular
Events with Icosapent Ethyl-Intervention Trial (REDUCE-
IT) tested the effect of icosapent ethyl, a stable eicosa-
pentaenoic acid ethyl ester, as add-on therapy with statins in
8179 patients with CV disease or diabetes and other CV risk
factors, and a fasting triglyceride level of 1.69-5.63 mmol/L
(150-499 mg/dL).74 The dose of icosapent ethyl was 2 g twice
daily and the median follow-up was 4.9 years. The primary
end point, a composite of CV death, MI, stroke, coronary
revascularization, or unstable angina, occurred in 17.2% of
the icosapent ethyl patients compared with 22.0% of the
placebo patients (hazard ratio, 0.75; 95% CI, 0.68-0.83;
P < 0.001).74 Although outcome data such as this are not
available for hypertriglyceridemic individuals living with HIV,
icosapent ethyl should now be considered as treatment for
such persons.
Inﬂammation is a potential therapeutic target for a
reduction of CV events, in persons with and without HIV
infection. Canakinumab, a monoclonal antibody targeting IL-
1b, was recently evaluated in a randomized, placebo-
controlled trial of 10,061 patients with previous MI and a
CRP level of  2 mg/L.75 The 3 doses of canakinumab that
were tested all reduced CRP, from 26% to 41%, but did not
affect LDL-C levels. At the intermediate and higher doses,
canakinumab reduced the primary composite end point of CV
death, MI, and stroke. Patients who had a CRP reduction to
< 2 mg/L experienced signiﬁcant reductions in CV events,
coronary heart disease death, and all-cause mortality, whereas
those without a CRP reduction to this level did not.76
Would canakinumab reduce CV risk in HIV-infected
subjects? Our group has shown that canakinumab signiﬁ-
cantly reduced IL-6 and CRP levels with no effect on CD4,
CD8, RNA viral levels, or lipids in a small study of subjects
with HIV infection.77 Another anti-inﬂammatory drug,
methotrexate, has been associated with reductions in CV
events among individuals with rheumatoid arthritis,78 an in-
ﬂammatory condition with elevated markers of inﬂammation
and elevated CV risk. The effect of low-dose methotrexate on
CV events was studied in the recently published Cardiovas-
cular Inﬂammation Reduction Trial (CIRT), in 4786 in-
dividuals with known CV disease or diabetes.79 The trial was
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placebo, methotrexate did not lower levels of IL-1b, IL-6, or
CRP, and had no effect on CV events.
Similarly, in a multicentre study, our group reported no
effect of low-dose methotrexate on inﬂammatory markers or
endothelial function80 but methotrexate did favourably affect
coronary artery echogenicity, a surrogate marker of plaque
composition.81 These preliminary studies with inﬂammatory
biomarkers as surrogate end points will hopefully lead to larger
trials of anti-inﬂammatory treatments with CV events as end
points among individuals living with HIV.Unique Features of Other CV Risk Factors in
HIV Patients
Whether HIV infection is associated with an increased risk
of diabetes has been controversial. PIs and thymidine ana-
logues, speciﬁcally stavudine, can cause insulin resistance82;
however, these drugs are rarely used nowadays because of their
toxicity. In a large cohort study from Denmark, the risk of
diabetes among HIV-infected individuals was nearly 3 times
higher than in the general population from 1996 to 1999, but
this excess was no longer present from 1999 to 2010.83
However, in a recent cross-sectional study from sub-Saharan
Africa, the prevalence of diabetes was higher in people living
with HIV compared with uninfected controls, as was the
prevalence of a glycated hemoglobin level of at least 6%.84
Lipodystrophy is a syndrome that results in central
adiposity from accumulation of fat in the dorsocervical region,
with increased or preserved visceral fat and peripheral fat
loss.3,41 Lipodystrophy develops in 20%-35% of patients
taking PIs or the NRTIs didanosine or stavudine. Newer PIs
such as atazanavir do not appear to cause lipodystrophy.
Lipodystrophy in HIV is commonly associated with compo-
nents of the metabolic syndrome: insulin resistance, impaired
glucose tolerance, hypertriglyceridemia, low HDL-C levels,
and hypertension. The insulin resistance associated with lip-
odystrophy can be severe, and might even precipitate diabetes.
Reported rates of the metabolic syndrome in persons living
with HIV range from 8.5% to 52%, with rates at the higher
end of this range found in Latin American countries and rates
at the lower end in multicentre studies in which patients had
less exposure to ART.82 Metabolic syndrome commonly de-
velops during the ﬁrst 3 years after initiation of an ART
regimen that includes lopinavir/ritonavir or stavudine. The
metabolic syndrome is a predictor of CV events and death in
HIV-infected individuals according to most studies.82
Hypertension and prehypertension have been shown to be
risk factors for CV events in HIV-infected persons, just as they
are for uninfected individuals.85 Similarly, chronic kidney dis-
ease), expressed as either albuminuria or a decreased glomerular
ﬁltration rate, is associated with an increased risk of CV events in
HIV-infected patients.86 In a cohort of 35,357 persons with
HIV, lower glomerularﬁltration rate was strongly associatedwith
higher CV risk.87 The prevalence of hypertension and chronic
kidney disease appears to be higher than normal inHIV-infected
persons among individuals exposed to some forms of ART.88
Smoking is highly prevalent among those infected with
HIV. In a large cohort study from Denmark, nearly half of
HIV patients were smokers compared with one-ﬁfth of un-
infected people.89 All-cause mortality rates were much higheramong smokers compared with nonsmokers with HIV. For
example, a 35-year-old person living with HIV had a median
life expectancy of 62.6 years (95% CI, 59.9-64.6) if a smoker
and 78.4 years (95% CI, 70.8-84.0) if a nonsmoker. Smoking
caused more lost life-years than HIV, 12.3 vs 5.1. The
population-attributable risk of death due to smoking was
61.5% in individuals with HIV and 34.2% among uninfected
people.
Smoking cessation programs appear to have the same
modest success rates in people with HIV as in noninfected
individuals. In a meta-analysis of 8 trials including 1822 HIV-
infected smokers, behavioural interventions increased absti-
nence rates by approximately half (relative risk, 1.51; 95% CI,
1.17-1.95).90 Training physicians who care for individuals
living with HIV to provide smoking cessation counselling and
treatment increased smoking cessation rates and decreased
relapse rates in one study.91 Potential drugedrug interactions
between ART and drugs for smoking cessation have not been
well studied. Studies of varenicline, bupropion, and nicotine
replacement therapy in persons with HIV have generally been
small, short, and uncontrolled, but have shown safety and
success rates similar to reports in uninfected subjects.92,93
The effect of smoking cessation on the rates of subsequent
CV events was reported for a large cohort in the D:A:D
study.94 Among those who stopped smoking, the incidence of
MI and other CV events began to decrease within the ﬁrst
year, with a further decrease thereafter. This pattern is similar
to what is seen in quitters without HIV infection, making
smoking cessation a very desirable therapeutic goal.Conclusion
Persons living with HIV are now older and at increased risk
for CV events. The presence of HIV approximately doubles
CV risk, as does either diabetes or hypertension.2 Lipid ab-
normalities are common among individuals with HIV infec-
tion, and their lipids are abnormally atherogenic, because of
several inter-related factors. Although clinical trial data with
lipid-lowering drugs is not yet available for those with HIV,
guidelines recommend that they be treated aggressively with
statins. Simvastatin and lovastatin are contraindicated with PIs
because of drugedrug interactions. Studies indicate that sta-
tins are underused in the setting of HIV,59,62,63 perhaps
because HIV specialists might not have the expertise to
manage CV risk, and because cardiologists do not have
expertise in HIV or appreciation of CV risk in this unique
population.Disclosures
Dr Waters has received remuneration from pharmaceutical
companies for participating in clinical trial committees of
investigational cholesterol drugs. Dr Hsue has received hon-
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